Surufatinib
As of the edition of 20 October 2026, Surufatinib is a small molecule: in active development; acts on FGFR1, FLT1 and FLT4 and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 96, 4 stopped early
- Disease areas
- Cancer; Digestive system; Hormones; Lungs and airways; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
4 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product4 company-target rows are on route A because of Surufatinib.
See the 4 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 11 | 0 | 4 | 0 |
| Phase 1 | 11 | 9 | 0 | 1 |
| Phase 2 | 68 | 10 | 30 | 3 |
| Phase 3 | 5 | 2 | 2 | 0 |
| Phase 4 | 1 | 0 | 1 | 0 |
| All trials | 96 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Hutchmed | Lead sponsor of trials | 2010 to now |
| Innovent Biologics | Lead sponsor of trials | 2020 to now |